IABS COLLABORATIONS
MUSICC – THE MUCOSAL IMMUNITY IN HUMAN CORONAVIRUS CHALLENGE
The Mucosal Immunity in Human Coronavirus Challenge (MUSICC) project is a global consortium that is laying the crucial groundwork needed to develop the next generation of COVID-19 vaccines.
The aim is for these vaccines to not only prevent severe disease but also stop SARS-CoV-2 and other coronaviruses from infecting people in the first place, thus blocking the spread of the virus.
Led by Imperial College London and co-funded by the European Union’s Horizon Europe Programme and the Coalition for Epidemic Preparedness Innovations (CEPI), the project will run controlled human infection studies where healthy volunteers will be infected with coronaviruses in order to understand how the immune system can prevent transmission and to test next-generation vaccines.
INNO4VAC – INNOVATIONS TO ACCELERATE VACCINE DEVELOPMENT AND MANUFACTURE
Inno4Vac is a public-private partnership that addresses scientific bottlenecks in vaccine development.
It proposes to develop predictive biological and mathematical models of vaccine performance and bio-manufacturing.
The IABS European Affiliate (IABS-EU) is part of consortia and has been selected to drive the regulatory part of the project.
ASFAVIP – AFRICAN SWINE FEVER ATTENUATED LIVE VACCINES IN PIGS
African swine fever (ASF), a category A disease listed in Article 5 of the EU Animal Health Law (Regulation (EU) 2016/429), has recently transformed from an exotic disease to a panzootic threat to domestic and wild suids world-wide. The socio-economic impact is huge and can be felt not only in the farming sector, but also in distantly related industries, such as the production of biomedical agents derived from pigs, or even sweets. It is therefore not surprising that ASF is also a STAR-IDAZ high-priority topic.
Although traditional control mechanisms are effective in conventional housing systems for domestic pigs, they quickly reach their limits in wild animals. Vaccination would therefore be of great importance. In Europe, this could be considered for wild boar in particular, but also for other endangered pig species worldwide and could therefore also contribute to the preservation of biodiversity. Great successes have been achieved with oral vaccines, for example in the fight against classical swine fever.
INNOVATIVE MEDICINES INITIATIVE (IMI) PROJECTS :
IMI is a European public-private partnership aiming to speed up the development of better and safer medicines. IMI is partly founded by the European Commission.
The IABS European Affiliate (IABS-EU) was part of consortia which have been selected by IMI to be the public partners of following consortia.
IABS-EU was selected to drive the regulatory part of those consortia.
Zoonoses Anticipation and Preparedness Initiative (ZAPI) – The Zoonoses Anticipation and Preparedness Initiative (ZAPI), part of the Innovative Medicines Initiative (IMI) public-private partnership, aims to enable swift response to major new infectious disease threats in Europe and throughout the world by designing new manufacturing processes (up to large scale) for delivering effective control tools (vaccines, antibodies/antibody-like molecules) against re-emerging zoonotic diseases with pandemic potential within a few months after the occurrence of first cases
VAC2VAC is a wide-ranging collaborative research project funded by IMI2 which aims to develop and validate quality testing approaches for both human and veterinary vaccines using non-animal methods.
DRIVE is a public private partnership that advances European cooperation in influenza vaccine effectiveness studies. It seeks to establish a sufficiently sized network for robust, high quality, brand-specific effectiveness estimates for all influenza vaccines used in the EU each season. The data generated through DRIVE is expected to increase the understanding of influenza vaccine effectiveness, lead to enhanced monitoring of influenza vaccine performance by public health institutes and allow manufacturers to fulfil regulatory requirements. DRIVE also aims to develop a sustainable and transparent governance model for public private partnerships.
MANCO, A EUROPEAN COMMISSION PROJECT :
